Vanda Pharmaceuticals Inc(VNDA)stock report

Vanda Pharmaceuticals Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of therapies to address unmet medical needs. Its product portfolio includes HETLIOZ (tasimelteon), Fanapt (iloperidone), Tradipitant (VLY-686), Trichostatin A and AQW051. It offers HETLIOZ for the treatment of Non-24-Hour Sleep-Wake Disorder (Non-24). HETLIOZ is in clinical development for the treatment of Pediatric Non-24, Jet Lag Disorder and Smith-Magenis Syndrome. It offers Fanapt for the treatment of schizophrenia. Fanapt has potential utility in various other disorders. Tradipitant is a small molecule neurokinin-1 receptor (NK-1R) antagonist, which is in clinical development for the treatment of chronic pruritus in atopic dermatitis. Trichostatin A is a small molecule histone deacetylase (HDAC) inhibitor. AQW051 is a Phase II alpha-7 nicotinic acetylcholine receptor partial agonist. AQW051 is indicated for the treatment of central nervous system disorders.

Market Cap:715.8M; Shares Outstanding:53.3M; Short Interest: 8.67%; Q3 2019(9/30/19): Cash 238M.

EPS and Sales:

Date EPS % last year % last quarter
2018.12.31 0.5 242.86% 66.67%
2019.3.31 -0.01 -114.29% 102.00%
2019.6.30 0.21 31.25% 2200.00%
2019.9.30 2.1 600.00% 900.00%


Date Sales % last year % last quarter
2018.12.31 193M 16.98% 37.86%
2019.3.31 47.71M 9.45% -75.28%
2019.6.30 107M 17.41% 124.27%
2019.9.30 166M 18.69% 55.14%


Insider Transactions:

Institution Ownership:

Total institutions: 752,no change
Shares hold: 54017.1k shares. Increased 0.489k
shares% hold: 101.27%,no change

Analyst Ratings:

Leave a Reply